Los Angeles Capital Management LLC Eiger Bio Pharmaceuticals, Inc. Transaction History

Los Angeles Capital Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 04, 2021	SELL	$7.98 - $12.29 $505,126 - $777,944	-63,299 Closed	0 $0
Q3 2020 Nov 02, 2020	SELL	$7.96 - $12.42 $141,027 - $220,045	-17,717 Reduced 21.87%	63,299 $515,000
Q2 2020 Aug 05, 2020	BUY	$5.4 - $13.37 $120,258 - $297,749	22,270 Added 37.91%	81,016 $777,000
Q1 2020 May 04, 2020	BUY	$4.91 - $14.7 $141,054 - $422,301	28,728 Added 95.7%	58,746 $399,000
Q4 2019 Feb 07, 2020	BUY	$9.77 - $15.66 $62,381 - $99,989	6,385 Added 27.02%	30,018 $447,000
Q3 2019 Nov 07, 2019	BUY	$9.59 - $12.0 $124,123 - $155,316	12,943 Added 121.08%	23,633 $242,000
Q2 2019 Jul 29, 2019	BUY	$9.54 - $14.96 $101,982 - $159,922	10,690 New	10,690 $113,000

748K

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $76.1M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

Get notified when there are updates to the investment portfolio of Los Angeles Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Los Angeles Capital Management LLC with notifications on news.